Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03406949
Title MGD009/MGA012 Combination in Relapsed/Refractory Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors MacroGenics

Advanced Solid Tumor


Obrindatamab + Retifanlimab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Medical Center Duarte California 91010 United States Details
University of Southern California Los Angeles California 90033 United States Details
Hoag Memorial Hospital Presbyterian Newport Beach California 92663 United States Details
Massachusetts General Hospital Boston Massachusetts 02214 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
START (South Texas Accelerated Research Therapeutics) - Midwest Grand Rapids Michigan 49546 United States Details
Sarah Cannon Research Institute Nashville Tennessee 37203 United States Details
Mary Crowley Cancer Center Dallas Texas 75251 United States Details
University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
Virginia Cancer Specialists Fairfax Virginia 22031 United States Details
*Shaded cells indicate that there was no data available from for the field